ArticleJournal of controlled release : official journal of the Controlled Release Society2019
Modulating smooth muscle cell response by the release of TGFβ2 from tubular scaffolds for vascular tissue engineering.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Resolving differential vascular graft remodeling using longitudinal multiphoton tracking in a 3D culture platform.Materials today. Bio · 2026Article
- Synthetic and Tissue-Engineered Vascular Grafts: Current Status, Emerging Technologies, and Clinical Prospects.Reviews in cardiovascular medicine · 2025Review
- Construction of vascular grafts based on tissue-engineered scaffolds.Materials today. Bio · 2024Review
- Advancements in wound management: integrating nanotechnology and smart materials for enhanced therapeutic interventions.Discover nano · 2024Review
- Nanofiber Scaffolds as Drug Delivery Systems Promoting Wound Healing.Pharmaceutics · 2023Review
- Engineering Smooth Muscle to Understand Extracellular Matrix Remodeling and Vascular Disease.Bioengineering (Basel, Switzerland) · 2022Review
- Acute Elution of TGFβ2 Affects the Smooth Muscle Cells in a Compliance-Matched Vascular Graft.Tissue engineering. Part A · 2022Article
- Medical Applications of Porous Biomaterials: Features of Porosity and Tissue-Specific Implications for Biocompatibility.Advanced healthcare materials · 2022Review
- Growth Factor Immobilization Strategies for Musculoskeletal Disorders.Current osteoporosis reports · 2022Review
- Programmable dual responsive system reconstructing nerve interaction with small-diameter tissue-engineered vascular grafts and inhibiting intimal hyperplasia in diabetes.Bioactive materials · 2022Article
- Electrospun fibre diameter and its effects on vascular smooth muscle cells.Journal of materials science. Materials in medicine · 2021Article
- The Construction of Multi-Incorporated Polylactic Composite Nanofibrous Scaffold for the Potential Applications in Bone Tissue Regeneration.Nanomaterials (Basel, Switzerland) · 2021Article
- A multilayered scaffold for regeneration of smooth muscle and connective tissue layers.Journal of biomedical materials research. Part A · 2021Article
- Applications of Biomaterials in 3D Cell Culture and Contributions of 3D Cell Culture to Drug Development and Basic Biomedical Research.International journal of molecular sciences · 2021Review
- Gelatin Matrices for Growth Factor Sequestration.Trends in biotechnology · 2020Review
- Progressive Reinvention or Destination Lost? Half a Century of Cardiovascular Tissue Engineering.Frontiers in cardiovascular medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Tissue engineering has gained considerable attention in the development of small diameter tissue engineered vascular grafts (TEVGs) for treating coronary heart disease. A properly designed acellular and biodegradable TEVG must encourage the infiltration and growth of vascular smooth muscle cells (SMCs). Our group has previously shown that increasing levels of TGFβ2 can differentially modulate SMC migration and proliferation. In this study, tubular electrospun scaffolds loaded with TGFβ2 were fabricated using various ratios of gelatin/polycaprolactone (PCL), resulting in scaffolds with porous nano-woven architecture suitable for tissue ingrowth. Scaffold morphology, degradation rate, TGβ2 release kinetics, and bioactivity were assessed. TGFβ2 was successfully integrated into the electrospun biomaterial that resulted in a differential release profile depending on the gelatin/PCL ratio over the course of 42 days. Higher TGFβ2 elution was obtained in scaffolds with higher gelatin content, which may be related to the biodegradation of gelatin in culture media. The biological activity of the released TGFβ2 was evaluated by its ability to affect SMC proliferation as a function of its concentration. SMCs seeded on TGFβ2-loaded scaffolds also showed higher densities and infiltration after 5 days in culture as compared to scaffolds without TGFβ2. Our results demonstrate that the ratio of synthetic and natural polymers in electrospun blends can be used to tune the release of TGFβ2. This method can be used to intelligently modulate the SMC response in gelatin/PCL scaffolds making the TGFβ2-loaded conduits attractive for cardiovascular tissue engineering applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.